Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease

International Journal of COPD

Volumn 9, Issue , 2013, Pages 51-56

  Nath, Karthik D ^a,b   Burel, Julie G ^a   Shankar, Viswanathan ^c   Pritchard, Antony L ^a   Towers, Michelle ^b   Looke, David ^a,b   Davies, Janet M ^a   Upham, John W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

COPD; Human infuenza; Humoral immunity; Infuenza vaccines

Indexed keywords

CORTICOSTEROID; FLU VAX; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 21; UNCLASSIFIED DRUG;

AGE; AGED; AIRWAY OBSTRUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MALE; PROSPECTIVE STUDY; SEROCONVERSION; SINGLE DRUG DOSE; SMOKING; T LYMPHOCYTE; VERY ELDERLY;

COPD; HUMAN INFLUENZA; HUMORAL IMMUNITY; INFLUENZA VACCINES; VACCINATION;

ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEMAGGLUTINATION TESTS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; VACCINATION;

EID: 84891390764     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S53590     Document Type: Article

References (25)

1. Rothbarth PH, Kempen BM, Sprenger MJ. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:1682-1685.
2. De Serres G, Lampron N, La Forge J, et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009;46:129-133.
3. Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy. 2011;66:25-31.
4. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1):CD002733.
5. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403.
6. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24: 1159-1169.
7. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125:2011-2020.
8. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53:1-40.
9. Yerkovich ST, Hales BJ, Carroll ML, et al. Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulm Med. 2012;12:37.
10. Cruijff M, Thijs C, Govaert T, Aretz K, Dinant GJ, Knottnerus A. The effect of smoking on influenza, influenza vaccination efficacy and on the antibody response to influenza vaccination. Vaccine. 1999;17: 426-432.
11. Jefferson T, Di Pietranton JC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;(2):CD004876.
12. Gross PA, Quinnan GV Jr, Weksler ME, Setia U, Douglas RG Jr. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine. 1989;7:303-308.
13. Hanania NA, Sockrider M, Castro M, et al; American Lung Association Asthma Clinical Research Centers. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004;113:717-724.
14. Gomez F P, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2002;8:81-86.
15. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180:1189-1195.
16. Halliley JL, Kyu S, Kobie JJ, et al. Peak frequencies of circulating human infuenza-specifc antibody secreting cells correlate with serum antibody response after immunization. Vaccine. 2010;28:3582-3587.
17. Agusti A, Soriano JB. COPD as a systemic disease. COPD. 2008;5: 133-138.
18. D'Alessio DJ, Cox PM Jr, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA. 1969;210:485-489.
19. Howells CH, Vesselinova-Jenkins CK, Evans AD, James J. Influenza vaccination and mortality from bronchopneumonia in the elderly. Lancet. 1975;1:381-383.
20. Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C Jr. Failure to respond to infuenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med. 1978;92:822-828.
21. Beyer WE, Palache AM, Sprenger MJ, et al. Effects of repeated annual infuenza vaccination on vaccine sero-response in young and elderly adults. Vaccine. 1996;14:1331-1339.
22. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. J Infect Dis. 1976;134:48-58.
23. Busse W W, Peters S P, Fenton MJ, et al. Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol. 2011;127:130-137, 137. e1-e3.
24. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R; Family Medicine Group of Pianiga. MF59-adjuvanted infuenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine. 2007;25:3955-3961.
25. Burel JG, Nath K, Pritchard AL, et al. Impaired immune response to infuenza vaccination in chronic obstructive pulmonary disease. J Vaccines Vaccin. 201; http://dx.doi.org/10.4172/2157-7560.S4-001. Accessed May 1, 2013.